The research team focused on the relationship between PGK1 and acute kidney damage, meticulously delineating the molecular cascade that connects metabolic enzymes to ferroptosis, a form of programmed cell death characterized by iron-dependent lipid peroxidation. Ferroptosis has emerged in recent years as a critical mechanism underpinning organ ischemia-reperfusion injury and other pathological insults. Understanding how PGK1 inhibition intersects this pathway offers new hope for therapeutic intervention.

PGK1 is traditionally known as a key glycolytic enzyme, catalyzing the conversion of 1,3-bisphosphoglycerate to 3-phosphoglycerate, generating ATP in the process. However, Zhu et al. discovered that aside from its metabolic function, PGK1 serves as a regulatory hub that influences the activity of pyruvate kinase M2 (PKM2), an isoform implicated in metabolic reprogramming in stressed or injured tissues. The inhibition of PGK1 was found to inactivate PKM2, setting off a cascade that ultimately modulates the activity of arachidonate 12-lipoxygenase (ALOX12), a critical enzyme in lipid peroxidation.

This intricate pathway is pivotal because ALOX12 catalyzes the oxidation of polyunsaturated fatty acids in cell membranes, a key step in the execution of ferroptosis. By suppressing PGK1, the researchers effectively blocked the PKM2/ALOX12 axis, thereby diminishing lipid peroxidation and protecting renal tubular cells from ferroptotic death. This was confirmed through rigorous in vivo studies using male mice models of acute kidney injury.

The choice of male mice was intentional, driven by the need to control for sex-specific differences in renal pathology and ferroptosis susceptibility. Notably, the intervention led to marked preservation of kidney function, reduced histological damage, and decreased levels of renal biomarkers indicative of injury. These findings underscore the therapeutic potential of targeting metabolic pathways to mitigate ferroptosis in AKI.

Zhu and colleagues employed an array of molecular biology techniques to substantiate their findings, including Western blotting, immunohistochemistry, and mass spectrometry-based lipidomics. These methods elucidated the suppression of PGK1 expression and the downstream effects on PKM2 phosphorylation status, revealing a tight regulatory network that governs ferroptotic cell death. Lipidomic profiling demonstrated reduced accumulation of oxidized phospholipids, providing biochemical evidence of attenuated ferroptosis.

The significance of this study extends beyond the kidney. Because ferroptosis has been implicated in multiple diseases ranging from neurodegeneration to cancer, the identification of PGK1 as a modulator of this pathway presents a broad spectrum of translational opportunities. Pharmacological agents or gene therapies designed to inhibit PGK1 could serve as powerful tools to curb ferroptosis-driven damage in diverse tissues.

In clinical contexts, AKI manifests as a rapid deterioration of renal function and contributes to the progression of chronic kidney disease if left unchecked. Currently, treatment options remain largely supportive, including fluid management and dialysis, with no approved agents that directly target the underlying molecular mechanisms of injury. The research by Zhu et al. paves the way for innovative therapeutics that can precisely dial down ferroptosis and preserve renal architecture and function.

Another exciting aspect of the study was the demonstration of reversibility. The team showed that pharmacological inhibitors of PGK1 administered after injury onset could still provide renoprotection, highlighting a therapeutic window that is clinically relevant. This finding heightens the translational relevance of their work, as it supports the feasibility of treating AKI even after diagnosis.

Mechanistically, the study illuminated how metabolic remodeling during AKI exacerbates oxidative stress and lipid peroxidation. PGK1 inhibition appears to recalibrate energy metabolism, reducing the overactivation of PKM2 and preventing the lethal accumulation of lipid hydroperoxides catalyzed by ALOX12. This delicate balance between metabolism and redox biology calls for further exploration to optimize targeted interventions.

One of the more intriguing discoveries was the interplay between PGK1 and PKM2 outside their canonical roles in metabolism. The notion that metabolic enzymes also serve as signaling molecules adds complexity but also therapeutic leverage. By targeting PGK1, researchers can indirectly modulate pyroptotic signals, leading to an integrated approach that disrupts crosstalk between metabolism and cell death.

The implications of this work extend into personalized medicine. Identification of biomarkers linked to PGK1 activity and ferroptosis could enable risk stratification and targeted treatment of patients prone to AKI, such as those undergoing major surgery, sepsis, or nephrotoxic drug exposure. This precision approach would improve outcomes and reduce healthcare burdens globally.

Future studies are warranted to explore the long-term effects of PGK1 modulation and to validate these findings in human tissues. Although the mouse model provides compelling evidence, translation to human clinical settings requires extensive safety and efficacy testing. Importantly, sex differences and comorbidities must be factored into subsequent research to ensure robust applications.

In conclusion, the work by Zhu et al. represents a monumental advance in understanding acute kidney injury by unmasking a previously underappreciated metabolic nexus that controls ferroptosis. Targeting PGK1 to dampen the PKM2/ALOX12 pathway provides a novel—and practical—therapeutic avenue to prevent or ameliorate AKI. This study not only opens new doors in nephrology but also enriches our broader comprehension of ferroptotic mechanisms in disease. As clinicians and researchers eagerly anticipate future developments, this discovery propels us toward a future where metabolic reprogramming could safeguard kidney health against the ravages of acute injury.

Subject of Research: Acute kidney injury and molecular mechanisms involving metabolism and ferroptosis

Article Title: Inhibition of PGK1 ameliorates acute kidney injury through inactivating the PKM2/ALOX12/ferroptosis pathway in a study with male mice

Article References:
Zhu, XX., Meng, XY., Zhang, AY. et al. Inhibition of PGK1 ameliorates acute kidney injury through inactivating the PKM2/ALOX12/ferroptosis pathway in a study with male mice. Nat Commun 16, 9436 (2025). https://doi.org/10.1038/s41467-025-64480-1

Image Credits: AI Generated

The research meticulously harnesses various human and murine cell lines, including HT1080, HT29, HeLa, and NIH-3T3, cultivating them under tightly controlled laboratory conditions to explore the influence of oestradiol and its derivatives. Employing state-of-the-art CRISPR-Cas9 gene editing, guided RNAs (gRNAs) were designed and inserted into plasmids targeting key genes implicated in ferroptotic pathways, such as CBS, CTH, AIFM2, ESR1, and FAR1. This genetic manipulation facilitated a granular analysis of the molecular players that orchestrate ferroptosis, allowing the team to modulate gene expression with remarkable precision.

Central to the investigation was the induction of ferroptosis using an array of established ferroptosis inducers (FINs), including erastin, RSL3, FIN56, and FINO2, representing the diverse classes of FINs that perturb cellular homeostasis through distinct biochemical routes. The team further examined necrotic pathways via thioredoxin reductase inhibition, expanding the scope of cell death modalities studied. Quantitative assessments of cell viability and death were conducted using flow cytometry techniques employing annexin V and 7-AAD staining, offering a high-resolution temporal and phenotypic picture of cell fate post-treatment.

Western blot analysis emerged as a crucial technique, revealing the expression dynamics of pivotal proteins such as ACSL4, GPX4, and ESR1, among others. These assays confirmed not only the efficacy of genetic knockouts but also the modulation of ferroptosis-sensitive proteins in response to hormonal treatment and gene editing. Importantly, the use of freshly isolated renal tubules from murine models enabled the extrapolation of cellular phenomena to organ-level responses, bridging the gap between in vitro and in vivo observations.

The work extended to primary renal tubule isolation from mice, pigs, and humans, adhering to stringent ethical standards and leveraging advanced enzymatic digestion protocols to preserve tubule integrity. These tubules served as a biologically relevant microsystem to test therapeutic interventions. Through lactate dehydrogenase (LDH) release assays, a sensitive marker for cellular membrane integrity and necrosis, the research delineated the extent of ferroptosis-induced damage and the protective efficacy of oestradiol and related compounds under ischemia-reperfusion injury (IRI) conditions.

Intricately designed in vivo experiments on murine models, including tamoxifen-inducible Gpx4 knockout mice and bilateral kidney IRI models, corroborated the protective effects of estradiol and its analogues. These models were subjected to precisely timed ischemic insults, with intervention arms receiving ferrostatins such as Fer-1 and UAMC-2303 or 2-hydroxyoestradiol, illuminating the therapeutic potential of these molecules in renal contexts. Ovariectomy and subsequent IRI surgeries elucidated the consequences of endogenous estrogen depletion and reaffirmed the hormone’s key role in mitigating AKI.

Sophisticated imaging and analytical techniques supplemented these interventions. Time-lapse fluorescence microscopy, utilizing SYTOX Green and mitochondrial tracers, provided real-time visualization of cellular demise within renal tubules, accentuating the sex-dependent nuances in ferroptotic vulnerability. Electron microscopy further detailed ultrastructural alterations in tubules, affirming the biochemical findings.

The study also employed cutting-edge lipidomics and mass spectrometry-based steroid hormone detection to quantify the molecular shifts induced by ferroptosis and hormonal interventions. Ultra-performance liquid chromatography coupled to tandem mass spectrometry enabled the precise measurement of sulfur-containing metabolites and oestradiol derivatives within kidney tubules. These data exposed the biochemical crosstalk between sulfur metabolism, steroid homeostasis, and ferroptotic regulation, uncovering novel molecular underpinnings of kidney resilience.

Simulated liposomal oxidation assays reinforced the mechanistic insights, demonstrating the radical-trapping antioxidant (RTA) capacities of estradiol derivatives in complex lipid environments. These assays, using egg phosphatidylcholine liposomes, unveiled the efficacy of these compounds in mitigating lipid peroxidation driven by di-tert-undecyl hyponitrite (DTUN), thereby confirming their antioxidant prowess in cell membrane mimetics.

Collectively, these multi-layered experimental approaches deliver compelling evidence positioning oestradiol as a potent modulator of ferroptosis, offering multifaceted protection against acute kidney insult. This study not only advances fundamental cell death biology but also charts new avenues for therapeutic exploration targeting steroid hormone pathways in renal disease.

Moving beyond basic science, this research holds immense translational promise. Acute kidney injury, a frequent and severe clinical complication, currently lacks effective targeted therapies. By elucidating the hormonal determinants that shield renal tissues from oxidative death pathways, this work paves the way for innovative treatments that exploit endogenous protective mechanisms. The detailed sex-specific analyses further underscore the importance of personalized medicine approaches, acknowledging the divergent vulnerabilities and treatment responses across genders.

Furthermore, the coupling of advanced gene editing with precise biochemical assays exemplifies a new era of mechanistic biology where molecular manipulations can be systematically linked to functional outcomes. The meticulous use of multiple animal models and primary human tissues reinforces the robustness and clinical relevance of these findings.

This research also invites revisiting the role of steroid hormones in other ferroptosis-related pathologies. Given that ferroptosis has been implicated in diverse conditions ranging from neurodegeneration to cancer, the regulatory role of oestradiol may transcend renal biology, necessitating broader investigations into hormonal modulation as a universal protective strategy.

In conclusion, this seminal work unravels how multiple functions of oestradiol intricately inhibit ferroptosis, thereby safeguarding renal integrity during acute injury. These insights herald a paradigm shift in understanding cell death regulation by endogenous hormones and open promising therapeutic horizons for managing AKI and likely other ferroptosis-associated diseases.

Subject of Research: Mechanisms of ferroptosis inhibition by oestradiol and its role in acute kidney injury.

Article Title: Multiple oestradiol functions inhibit ferroptosis and acute kidney injury.

Article References:
Tonnus, W., Maremonti, F., Gavali, S. et al. Multiple oestradiol functions inhibit ferroptosis and acute kidney injury. Nature (2025). https://doi.org/10.1038/s41586-025-09389-x

Image Credits: AI Generated